Tofacitinib
Frequent switching between JAK inhibitors observed in patients with RA
PHILADELPHIA — Patients with rheumatoid arthritis frequently switched between JAK inhibitors in Australia, according to a presentation at ACR Convergence 2022.
‘No clear increased risk’ for CV events with tofacitinib in ORAL Surveillance post-hoc
PHILADELPHIA — There is “no clear increased risk” for major adverse cardiovascular events associated with tofacitinib, according to a post-hoc analysis of the ORAL Surveillance trial presented at ACR Convergence 2022.
Patients disabled with RA have 23% higher CVD risk than those considered employable
Patients with rheumatoid arthritis who are on Social Security Disability Insurance have a 23% higher risk for cardiovascular disease compared with those considered employable, according to data published in Arthritis Research & Therapy.
VIDEO: ‘No difference’ between ustekinumab, tofacitinib for steroid-free remission in UC
CHARLOTTE, N.C. — In a Healio video exclusive, Rahul Dalal, MD, MPH, reported ustekinumab and tofacitinib yielded similar safety and efficacy in the treatment of a small subset of adult patients with ulcerative colitis.
Major cardiac events not more common in patients receiving JAK inhibitors vs adalimumab
The risks for major adverse cardiac events and venous thromboembolism in patients with rheumatoid arthritis did not significantly differ between those receiving Janus kinase inhibitors or adalimumab, according to data.
Third COVID vaccine provides ‘significant boost’ in antibody response in patients with IBD
Immunosuppressed patients with inflammatory bowel disease who received a third COVID-19 vaccine demonstrated improved antibody binding, although the response was reduced in patients receiving infliximab and tofacitinib.
Infections more common in patients with RA receiving tofacitinib vs TNF inhibitors
Infections are more common in patients with rheumatoid arthritis who receive tofacitinib compared with those who receive TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.
Head-to-head studies ‘would be nice’: More data needed to ascertain JAK inhibitor risks
More trials are needed to fully elucidate the cardiovascular, infection and malignancy risks linked to Janus kinase inhibitors in rheumatoid arthritis, said a presenter at the 2022 Association of Women in Rheumatology annual conference.
Tofacitinib not associated with higher rates of malignancies than TNF inhibitors
Tofacitinib shows no evidence of an increased risk for malignancies compared with TNF inhibitors when used to treat rheumatoid arthritis, according to data published in Arthritis & Rheumatology.